Get this report today!
Table of Contents
Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure
GBI Research, leading business intelligence provider, has released its latest research report, ‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’, which provides insights into major drug failures during 2005–2010. The 20 drugs included in the report belong to key pharmaceutical companies and were undergoing research for a major indication. The report also includes the total expenditure of top pharmaceutical companies in R&D throughout 1996–2009, and an analysis of the financial loss faced by such companies when a drug fails in the late stages of development.
GBI Research discovered that the economic impact of drug failure during late stage development increased in relation to the escalating cost of development for new therapeutic agents. The main cause of drug failure in Phase III, when the efficacy of the drug is already evaluated, is either its safety measures or its ability to demonstrate any additional benefits in a larger population over a longer time period. Pharmaceutical companies have recently invested substantial amounts of money in R&D processes; in order to combat the threat of patent expires of blockbuster drugs, and to increase the chances of discovering a drug which could generate considerable revenue for the company. If a drug receives approval and is patented, companies’ returns are significantly higher than the amount invested in R&D.
The attrition of molecules occurs at various stages of the trial during drug development process. The majority of molecules fail at the initial stages of development, such as pre-clinical studies and Phase I and II. Pharmaceutical companies face huge losses when drugs fail in the late stage of trials, such as Phase III and the post-marketing stage. According to analysis conducted during 2005–2010, it was found that the number of drugs dropped from the pipeline increased from 2003 to 2007 and furthermore decreased from 2007 to 2010. Many drugs have been discontinued during the course of clinical trials, due to safety and efficacy issues. The decision to discontinue the development of a drug is taken by the health authorities and is based on interim analysis. If the drug is not able to demonstrate any additional benefits over existing therapies, or it has issues related to patient safety, the drug fails to receive approval from health authorities.
The scope of this report includes -
- Identification of top 20 R&D drug failures
- Unmet need in efficacy and safety for all failed drugs
- Phase II results and the reasons for conducting Phase III
- The reasons for failure and lack of available options for a particular therapeutic area
- Conclusion regarding late-stage drug failures based on the analysis of the top 20 drug failures
Reasons to buy
The report will enhance your decision making capability and will allow you to -
- Build an understanding of recent top R&D late stage drug failures
- Analyze the effect of safety and efficacy parameters on major drug failures
- Identify the unmet needs for a particular indication with the highest drug failures
- Understand the most common reasons for drug failure in late stage of development
- Identify the cost involved in R&D by analyzing the expenditure done by top pharmaceutical companies
Talk to Louis
+1 718 618 4302
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Life Sciences BPO Market [Contract Research Organizations (Drug Discovery, Pre-Clinical, Clinical Trials, Medical Writing, Pharmacovigilance, Risk-Based Monitoring, Clinical Data Management, Biostatistics)and ...
The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and ...
This report encompasses market estimations for biopreservation market for the forecast period 2013 to 2019. The market size is forecasted considering 2012 as the base year and is represented in terms of ...
... Complexities, and so on). Within the cro market, the largest segment was that of drug discovery. Based on various analyses, the report also anticipates that the market for clinical data management services ...
... Learn/confirm and predict phase vi registering and labeling (maa) uncertainty confident and drug and disease paediatric strategy & investigation plan scientific advice clinical trial ...
... Company. The transaction positions telerx for further expansion of one of its key vertical businesses 8 nov 12 smo n/a augment number of clinical trial sites to 57. Increase access to patients, conduct ...
Reportlinker.com © Copyright 2014. All rights reserved.